Alopexx Enterprises, LLC was founded in 2011 as an outgrowth of a collaboration that led to the successful development and licensing of an early stage pharmaceutical product. That collaboration began in 2006 when the initial company, Alopexx Pharmaceuticals obtained the rights to develop a fully human monoclonal antibody that can be used for the treatment and prevention of staphylococcal and other serious infections.  Following GMP production and preliminary clinical testing the antibody was licensed in 2010 to Sanofi Aventis for $375 million dollars in total, as well as royalties on sales of products commercialized under the license.

The success that Alopexx Pharmaceuticals enjoyed can be attributed to factors that go beyond the scientific importance and relevance of the antibody.  It also depended in large part on the financial support and development expertise that permitted the successful funding, development and ultimate partnering with a major pharmaceutical company.

In its early stages Alopexx Pharmaceuticals relied on a team of experienced consultants to develop and partner the program.  However following the successful licensing of the antibody to Sanofi it was decided to retain the management team and move onto other development opportunities in the health care sector.  Alopexx Enterprises was formed to maintain that management expertise which when combined with financial resources described below permits both the funding and development of a wide range of programs.